Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$1.95 + 0.01 (0.00%)
Day High:$2.11
Day Low:$1.92
Volume:112,913
10/15/184:00 p.m. ET
Delayed at least 15 minutes.

Julia Balanova
Ph + 646 378 2936
jbalanova@soleburytrout.com


 

Recent News

MORE
DateTitle 
Oct 01, 2018CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
- Trial to continue to full enrollment of all three treatment arms - - Full data set expected to support determination of an optimal dose for planned Phase 3 development in patients with severe thrombocytopenia - - Independent Data Monitoring Committee did not identify significant safety concerns - SEATTLE, Oct. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monit... 
Printer Friendly Version
Sep 26, 2018CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
SEATTLE, Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel. Presentation details: Event: Cantor Fitzgerald Global Healthcare Conference Date: ... 
Printer Friendly Version
Aug 02, 2018CTI BioPharma Reports Second Quarter 2018 Financial Results
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, Aug. 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter and six months ended June 30, 2018. In July 2018, CTI BioPharma announced the continuation without modification of the PAC203 Phase 2 study following a planned interim review by an Independent Data Monitoring Committee. The Company also announced a pacritinib program update following a ... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.